FDA Brief

Warning letters Drugs

FDA warning letter to

Natuzem

High riskIssued Oct 26Posted Nov 3Center for Drug Evaluation and Research (CDER)

FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

What happened

FDA reviewed Natuzem's website, https://natuzem.com/, in September 2026 and found the products marketed with claims to treat diseases. Because those claims make the products drugs, and FDA has no approved applications for them, FDA calls them unapproved new drugs. FDA also said earlier lab tests of products with similar names found undeclared drug ingredients, though FDA has not sampled these specific products from Natuzem's inventory.

What FDA found

  1. The website claims these products treat or prevent diseases, such as reducing premature ejaculation, treating arthritis, or protecting against bone cancer, which makes them drugs under the law.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128
  2. The products are not generally recognized as safe and effective, and FDA has no approved application for any of them, so they are unapproved new drugs.

    Section 201(p) and 505(a) of the FD&C Act, 21 U.S.C. 321(p) and 355(a)
  3. Shipping these unapproved drugs across state lines violates the law.

    Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
  4. FDA says it is the firm's legal duty to make sure products it sells contain no undeclared or harmful ingredients, after earlier tests of similarly named products found hidden drug ingredients.

What FDA wants

Send a written response to FDAAdvisory@fda.hhs.gov within 15 business days of receiving the letter, listing the specific steps taken to fix the violations and to prevent them from happening again, with supporting documents, and put reference number 737558 in the subject line.

Who should pay attention

  • online sellers of herbal or joint-health products shipping to the United States
  • consumers buying arthritis or sexual-health products from foreign websites
  • distributors and marketplaces that list products such as Reumofan Plus or Artrifan King

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  3. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk